NVAX— NOVAVAX INC

MaterialsBiotechnology$1.3B mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Revenues	$1.12B+64.7%	$682.2M-30.7%	$983.7M-50.4%	$1.98B
Cost of sales	$73.0M-64.0%	$202.7M-41.0%	$343.8M-61.9%	$902.6M
Research and development	$342.3M-12.5%	$391.2M-47.0%	$737.5M-40.3%	$1.24B
Selling, general, and administrative	$157.5M-53.3%	$337.2M-28.1%	$468.9M-4.0%	$488.7M
Impairment of assets held for sale	$97.8M	$0	$0	—
Total expenses	$670.7M-28.0%	$931.1M-39.9%	$1.55B-41.0%	$2.63B
Income (loss) from operations	$452.8M+281.9%	-$248.9M+56.1%	-$566.5M+12.1%	-$644.7M
Interest expense	-$22.5M-12.3%	-$20.1M-39.3%	-$14.4M+27.5%	-$19.9M
Loss on debt extinguishment	-$28.7M	$0	$0	—
Gain on disposition of Novavax CZ assets	$0-100.0%	$51.9M	$0	$0
Other income, net	$40.6M+0.5%	$40.4M+6.7%	$37.9M+245.5%	$11.0M
Income (loss) before income tax expense	$442.2M+350.4%	-$176.6M+67.5%	-$543.0M+16.9%	-$653.6M
Income tax expense	-$1.9M+82.9%	-$10.9M-435.9%	-$2.0M+52.7%	-$4.3M
Net income (loss)	$440.3M+334.8%	-$187.5M+65.6%	-$545.1M+17.2%	-$657.9M
Basic (in usd per share)	$2720.00+321.1%	-$1230.00+77.3%	-$5410.00+35.7%	-$8420.00
Diluted (in usd per share)	$2580.00+309.8%	-$1230.00+77.3%	-$5410.00+35.7%	-$8420.00
Basic (in shares)	162.0M+6.4%	152.2M+51.0%	100.8M+28.9%	78.2M
Diluted (in shares)	173.1M+13.7%	152.2M+51.0%	100.8M+28.9%	78.2M
Product sales
Licensing, royalties, and other
Grants

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 13 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.